Subscribe to
our newsletters

Subscribe to our newsletters!

Subscribe to our newsletter and get the latest news from the Nordics straight to your inbox.

Search in Nordic Life Science Insight

CanimGuide Therapeutics AB

CanimGuide Therapeutics AB

A company with …

a novel, simple but sophisticated and highly innovative, peptide approach to immuno-oncology.

CanImGuide has discovered, and thoroughly demonstrated, that a previously unknown immunosuppressive peptide named P3028 is formed in malignant tumors through the breakdown of albumin. This intra-tumoral albumin peptide binds to the LFA-1 receptor (an integrin with a key role in immune cell functioning) and is thereby blocking an important component in the natural immune defense that normally contributes to kill cancer cells.

Our Solution

The nonclinical studies performed by CanImGuide have clearly demonstrated that this peptide drug treatment is efficacious in essentially all torms of spontaneous tumors in dogs (which have a similar immune system and develop cancer similar to humans) and that it is very safe. Based on the mode of action and the safety profile, as well as an initial checkpoint inhibitor combo study, it is anticipated that this novel drug can be used both as monotherpay and in combination with other anti-cancer treatments. Läkemedelsverket reviewed the submission file of CanImGuide earlier this year and have given their approval to start testing the drug (P28R) in patients with head-and-neck cancer. This clinical trial will now be initiated during 2018.

Get in touch with us!

Visit us

CanImGuide Therapeutics AB Scheelevägen 2, 223 81 Lund, Sweden

Send us mail

Our published articles

No items found.
Date
Title
Category
No articles found.
CanimGuide Therapeutics AB

CanimGuide Therapeutics AB

A company with …

a novel, simple but sophisticated and highly innovative, peptide approach to immuno-oncology.

CanImGuide has discovered, and thoroughly demonstrated, that a previously unknown immunosuppressive peptide named P3028 is formed in malignant tumors through the breakdown of albumin. This intra-tumoral albumin peptide binds to the LFA-1 receptor (an integrin with a key role in immune cell functioning) and is thereby blocking an important component in the natural immune defense that normally contributes to kill cancer cells.

Our Solution

The nonclinical studies performed by CanImGuide have clearly demonstrated that this peptide drug treatment is efficacious in essentially all torms of spontaneous tumors in dogs (which have a similar immune system and develop cancer similar to humans) and that it is very safe. Based on the mode of action and the safety profile, as well as an initial checkpoint inhibitor combo study, it is anticipated that this novel drug can be used both as monotherpay and in combination with other anti-cancer treatments. Läkemedelsverket reviewed the submission file of CanImGuide earlier this year and have given their approval to start testing the drug (P28R) in patients with head-and-neck cancer. This clinical trial will now be initiated during 2018.

Get in touch with us!

Visit us

CanImGuide Therapeutics AB Scheelevägen 2, 223 81 Lund, Sweden

Send us mail

Our published articles

No items found.
Date
Title
Category
No articles found.